anti PRLR antibody drug-conjugates (Regeneron Pharmaceuticals)

N/A

Report date: 2025/06/11 10:38:13

Base Information

Drug Nameanti PRLR antibody drug-conjugates (Regeneron Pharmaceuticals)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionProlactin receptor modulatorsReceptor protein-tyrosine kinase erbB-2 modulators
TargetsProlactin receptorReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A